Overview

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Status:
Recruiting
Trial end date:
2024-07-23
Target enrollment:
Participant gender:
Summary
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb